The Challenge of Clinical Trials During COVID-19

article image

While clinical research at most healthcare systems paused for much of this spring, with a fallout that has yet to be calculated, cancer trials have been an exception. We look at Novocure's ongoing studies.

COVID-19’s more significant challenge for Novocure Inc. has been keeping its clinical trials on track. Because cancer cells in almost all solid tumors undergo the same or similar mitosis, the company has a robust R&D program and is exploring TTF’s potential in multiple solid-tumor cancers.

This article is restricted to subscribers only.

To continue reading, select one of the options below:

Existing Subscriber?

Sign In to continue reading.

Need Multi-User Access?

Gain access for your entire organization.

Get Quote Check to see if your company already has access

Subscribe to MedTech Strategist:

Actionable intelligence exploring the people, challenges, and opportunities impacting the global medtech community.

Subscribe to MedTech Strategist
Subscribe to ELITE Strategist

Become an ELITE Strategist and unlock access to both MedTech Strategist and MTS Market Pathways.

Subscribe to Elite


We're here to help! Please contact us at: